News | September 17, 2010

Angioplasty Balloon Integrates Embolic Capture Device

September 17, 2010 - The Food and Drug Administration (FDA) cleared the first device that combines an angioplasty balloon and an embolic capturing feature. Angioslide's Proteus device is presently indicated for use in the lower limbs during Percutaneous Transluminal Angioplasty (PTA) procedures.

Proteus joins the new class of medical devices aimed at treating peripheral arterial disease (PAD), one of the fastest-growing segments in the worldwide interventional marketplace. An estimated 10 million patients suffer from PAD in the United States alone, of whom approximately 1,000,000 undergo a revascularization or amputation procedure each year. PTA procedures are a common treatment for peripheral artery disease for opening up the artery to improve blood flow. However, one potential complication of a PTA procedure is debris from the artery wall being disturbed during the procedure and floating downstream. In the worst case, this debris can totally occlude the artery and cause complete lack of circulation to the lower limb.

The Proteus device combines a standard angioplasty balloon with a feature that can capture the debris that may be liberated during the PTA procedure. Proteus has the same characteristics as a standard angioplasty balloon, but the embolic capture feature allows debris to be trapped within the balloon and removed as the physician removes the angioplasty balloon at the end of the PTA procedure.

"I am very pleased with the use of the Proteus device in my patients," said Subhash Banerjee, M.D., Chief, Division of Cardiology, from VA North Texas Health Care System, Dallas, Texas. "It is simple to use and cost-effective and I can now be assured that my patients will have a significant reduction in risk from the PTA procedure."

"Being part of the company's Scientific Advisory Board from its early days, I am very excited that Proteus has received FDA clearance for use in the lower limbs. Proteus and Embolic Capture Angioplasty will reduce the risk of complications for our patients and in the future could become the gold standard for angioplasty procedures," said John Laird, M.D., Medical Director, UC Davis Vascular Center, Sacramento, Calif.

For more information: www.angioslide.com

Related Content

News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI).

The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI). This image shows how the covered stents used with the system connect to create a new arterial pathway.

News | Peripheral Artery Disease (PAD)| August 02, 2017
Aug.
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
Sponsored Content | Videos | Peripheral Artery Disease (PAD)| July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter
News | Chronic Total Occlusion (CTO)| June 28, 2017
June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus...
Shockwave Medical Announces U.S. Commercial Availability of Lithoplasty System
News | Peripheral Artery Disease (PAD)| June 26, 2017
Shockwave Medical recently announced two milestones for its Lithoplasty System for the treatment of calcified plaque in...
Overlay Init